| Company Name: |
Shanghai Chaolan Chemical Technology Center
|
| Tel: |
QQ:65489617 15618227136 |
| Email: |
info@SuperLan-chem.com |
| Products Intro: |
Product Name:PROTAC B-Raf degrader 1
CAS:2364367-27-9
Purity:98% HPLC Package:5MG;10MG;50MG;100MG,1G,5G,500G
|
| Company Name: |
ChemeGen(Shanghai) Biotechnology Co.,Ltd.
|
| Tel: |
18818260767 |
| Email: |
sales@chemegen.com |
| Products Intro: |
Product Name:PROTAC B-Raf degrader 1
CAS:2364367-27-9
Purity:98% Package:10 mg;50 mg;100 mg;500 mg;1 g;5 g;10 g
|
| Company Name: |
Guangzhou Younan Technology Co., Ltd
|
| Tel: |
020-020-82000279 18988968278 |
| Email: |
sales@ubiochem.com |
| Products Intro: |
Product Name:PROTAC B-Raf degrader 1
CAS:2364367-27-9
Purity:98% Package:5mg;10mg;50mg;100mg
|
|
| | PROTAC B-Raf degrader 1 Basic information |
| | PROTAC B-Raf degrader 1 Chemical Properties |
| Boiling point | 1136.9±65.0 °C(Predicted) | | density | 1.451±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C, stored under nitrogen | | solubility | DMSO : 25 mg/mL (32.73 mM; Need ultrasonic) | | pka | 10.68±0.40(Predicted) | | form | Solid | | color | Light yellow to yellow |
| | PROTAC B-Raf degrader 1 Usage And Synthesis |
| Biological Activity | PROTAC B-Raf degrader 1 (compound 2) is a proteolysis targeting chimera (PROTAC) for the degradation of B-Raf based on Cereblon ligand with anti-cancer activity[1].
The IC50 values of PROTAC B-Raf degrader 1 (compound 2) towards MCF-7, MDA-MB-231, HepG2, LO2 and B16 cells are 2.7 μM, 21.21 μM, 18.70 μM, 41.11μM and 22.68 μM, respectively[1].PROTAC B-Raf degrader 1 (5 or 10 μM) can accelerate the degradation of B-Raf by recruiting ubiquitin-proteasome system, and further affects the expression of Mcl-1, a downstream protein of B-Raf[1].MCF-7 cells achieve an apoptosis rate of 76.70% (64.00% early apoptosis, 12.70% late apoptosis) after 24 h incubation of PROTAC B-Raf degrader 1 with the concentration of 20 μM[1].PROTAC B-Raf degrader 1 arrests cell cycle at the G2/M phase[1]. | | References | [1]. Chen H, et al. Pomalidomide hybrids act as proteolysis targeting chimeras: Synthesis, anticancer activity and B-Raf degradation. Bioorg Chem. 2019 Mar 19;87:191-199. |
| | PROTAC B-Raf degrader 1 Preparation Products And Raw materials |
|